Fig. 1From: Thrombotic events following tocilizumab therapy in critically ill COVID-19 patients: a Façade for prognostic markersGeneral trend observed in lab values of COVID-19 patients prior to and post tocilizumab therapy and thrombotic events (not based on exact patient values)Back to article page